Tagged: phase 3 trials

Three Ways to Target Inefficiency in Clinical Development

Based on years of poor R&D productivity, the pharma industry is rethinking clinical development. Novartis CEO Joseph Jimenez is rethinking the traditional blockbuster.  Tomas Philipson and former FDA Commissioner Andrew von Eschenbach are rethinking  phase III trials. A third aspect of clinical development also requires rethinking but I’ll leave that for the end of this… Read more »